Alizé Pharma launches Phase I in type-2 diabetes

Docea Power in the Deloitte InExtenso Technology Fast 50
4 December 2013
OREGA Biotech closes its second financing round
13 April 2013

Alizé Pharma launches Phase I in type-2 diabetes

First clinical trial for AZP-531, the analogue of non-acylated ghrelin.